Related Experiment Videos
Mezlocillin pharmacokinetics in pediatric oncology patients
Abstract:
The pharmacokinetics of mezlocillin were studied in 31 children (age, 2 to 19 years) with malignancies and normal renal and hepatic functions. Mezlocillin was administered intravenously over 30 min every 4 h at doses ranging from 12.2 to 125 mg/kg. Blood samples were obtained over one dosage interval at steady state. For all patients, the mean clearance was 0.21 +/- 0.11 liter/h per kg, the mean distribution volume was 0.26 +/- 0.13 liter/kg, and the mean elimination half-life was 0.97 +/- 0.51 h. Trough concentrations were 23.0 +/- 29.9 mg/liter before the dose was administered and 20.4 +/- 27.5 mg/liter at the end of the dosing interval. Peak concentrations averaged 245 +/- 90.4 mg/liter, and average concentrations for the dosing interval were 83.7 +/- 40.4 mg/liter. There were no apparent effects of sex, malignancy, age, or dose on either the kinetic parameters or plasma concentrations. Overall, the disposition parameters for mezlocillin in this patient group were comparable to those reported in adults.
Insights
Pharmacokinetics of mezlocillin in pediatric oncology patients showed similar disposition parameters to adults. These findings support consistent dosing strategies for mezlocillin in children with malignancies and normal organ function.
Area of Science:
- Pharmacology
- Pediatric Oncology
- Antibiotic Pharmacokinetics
Background:
- Understanding drug disposition is crucial for optimizing therapeutic efficacy and safety in pediatric patients.
- Mezlocillin is a penicillinase-resistant penicillin antibiotic used to treat bacterial infections.
Purpose of the Study:
- To characterize the pharmacokinetics of mezlocillin in children diagnosed with malignancies.
- To compare mezlocillin disposition parameters in pediatric oncology patients to those reported in adult populations.
Main Methods:
- Intravenous administration of mezlocillin (12.2–125 mg/kg) every 4 hours to 31 pediatric patients (2–19 years) with normal renal and hepatic function.
- Blood sampling at steady state to determine pharmacokinetic parameters including clearance, distribution volume, and elimination half-life.
- Analysis of trough, peak, and average plasma concentrations over a dosing interval.
Main Results:
- Mean clearance: 0.21 ± 0.11 L/h/kg; Mean distribution volume: 0.26 ± 0.13 L/kg; Mean elimination half-life: 0.97 ± 0.51 h.
- Average trough concentrations: 23.0 ± 29.9 mg/L; Average peak concentrations: 245 ± 90.4 mg/L.
- No significant influence of sex, malignancy, age, or dose on pharmacokinetic parameters or plasma concentrations was observed.
Conclusions:
- The disposition of mezlocillin in pediatric oncology patients with normal renal and hepatic function is comparable to that observed in adults.
- These pharmacokinetic data support the established dosing regimens for mezlocillin in this specific pediatric population.
- Further research may explore the impact of altered renal or hepatic function on mezlocillin pharmacokinetics in children.